

8-Bromo-ATP Biochemical

8-Bromo-ATP

CATALOG #
AAA228337


PRODUCT SYNONYMS

8-Bromo-ATP; 8-Bromo-ATP biochemical


PRODUCT SPECIFICATIONS

Purity/Purification	98%
CAS	23567-97-7
Solubility	<1mg/ml refers to the product slightly soluble or insoluble
In vitro	8-Bromo-ATP (10-50 uM; 5 days) treatment shows cytotoxic to multiple myeloma[3]. Fluorescence measurements are made possible through the use of 8-Bromo-ATP, which selectively quenched certain tryptophan residues of the ATPase. 8-Bromo-ATP enhances the rate of dephosphorylation of native ATPase 2-3-fold when added in the absence of divalent cations[2]. Cell Viability Assay[3]Cell Line: MM 1.s cells Concentration: 10 uM, 20 uM, 30 uM, 40 uM, 50 uM Incubation Time: 5 days. Result: Showed cytotoxic to multiple myeloma.
Preparation and Storage	Powder: -20 degree C for 3 years In solvent: -80 degree C for 2 years

IMAGES



Structure
IL-17A modulator-2, CAS 2748749-47-3



Structure
IL-17A modulator-2, CAS 2748749-47-3

ADDITIONAL INFORMATION

Related Product Information for 8-Bromo-ATP biochemical	8-Bromo-ATP (8-Bromoadenosine 5'-triphosphate), an ATP analogue, is a purinergic P2X receptor agonist. 8-Bromo-ATP shows cytotoxic to multiple myeloma cells with an IC 50 of 23.1 uM.
References	1. Barrie Phillip MARTIN, et al. Preparation of amino acid amides as IL-17A modulators. WO2021239743 A1.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. Small volumes of product may become entrapped in the seal of the vial during shipment and storage; if necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the cap.